Involvement of the Soluble Urokinase Receptor in Chondrosarcoma Cell Mobilization

Table 2

Clinicopathological parameters and uPAR levels in tumour tissues and in plasma of patients with chondrosarcoma.

Patients	First clinical evaluation	Therapy	Survival from diagnosis (months)	uPAR grading^a	SuPAR (pg/mL)^b
1	P	Surgery	6	0	1094
2	P	Surgery	87	1	1.508
3	P + Lung M	Surgery	3	3	3.645
4	P + Lung M	Neoadiuvant chemotherapy and surgery	14	3	5.152
5	P	Surgery	9	2	1.556
6	P + Lung M	Surgery and chemotherapy	8	3	ND

P, primary tumor; M, metastasis; ^aImmunohistochemical staining of tumor frozen sections with R4 anti-uPAR mAb was graded as absent (grading 0), faint (grading 1), moderate (grading 2), or intense (grading 3). ^bDetermination of plasmatic SuPAR content by Elisa, expressed as pg SuPAR/mL plasma.